Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Progenics Pharmaceuticals
Progenics Pharmaceuticals
(PGNX)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Azedra
Iobenguane i
2018-07-30
—
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Iobenguane i 131
neoplasms
,
neuroendocrine tumors
Lutetium dotatate lu-177
neoplasms
,
neuroendocrine tumors
Aglatimagene besadenovec
neoplasms
,
urogenital neoplasms
,
neoplasms by site
,
male genital diseases
,
prostatic diseases
,
male genital neoplasms
,
genital diseases
,
glioblastoma
,
gliosarcoma
,
recurrence
,
prostatic neoplasms
,
castration-resistant prostatic neoplasms
,
adenocarcinoma
,
hypersensitivity
Ademetionine
prostatic neoplasms
Iobenguane i-131
neoplasms
,
neuroendocrine tumors
Aspartame
prostatic neoplasms
Piflufolastat f-18
neoplasms
,
urogenital neoplasms
,
neoplasms by site
,
male genital diseases
,
prostatic diseases
,
male genital neoplasms
,
genital diseases
,
recurrence
,
prostatic neoplasms
,
castration-resistant prostatic neoplasms
,
adenocarcinoma
,
hypersensitivity
Piflufolastat f18
neoplasms
,
urogenital neoplasms
,
neoplasms by site
,
male genital diseases
,
prostatic diseases
,
male genital neoplasms
,
genital diseases
,
recurrence
,
prostatic neoplasms
,
castration-resistant prostatic neoplasms
,
adenocarcinoma
,
hypersensitivity
Arm1
prostatic neoplasms
,
neoplasms
,
urogenital neoplasms
,
neoplasms by site
,
male genital diseases
,
prostatic diseases
,
male genital neoplasms
,
genital diseases
Arm2
prostatic neoplasms
,
neoplasms
,
urogenital neoplasms
,
neoplasms by site
,
male genital diseases
,
prostatic diseases
,
male genital neoplasms
,
genital diseases
Bolus
prostatic neoplasms
,
adenocarcinoma
Docetaxol
prostatic neoplasms
,
castration-resistant prostatic neoplasms
Evidence
prostatic neoplasms
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use